PharmaTelevision - Starpharma’s Nanotechnology

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Starpharma’s Nanotechnology

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Dr Jackie Fairley
CEO
Starpharma

Dr Jackie Fairley, CEO of Starpharma Holdings, discusses the recent deal that the company has signed with SSL International, the Durex® condom manufacturer. Although the company is a platform technology company it is resisting the temptation to diversify and intends to continue to concentrate on the pharmaceutical applications of dendrimers. Dr Fairley explains the reasoning behind their partnering strategies and how the company will see their way through this current economic crisis.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Starpharma Holdings Origin and its Dendritic technology

Fintan Walton:

Hello and welcome to PharmaVentures business review here in Melbourne, Australia. On this show I have Jackie Fairley, who is the CEO of Starpharma Holdings based here in Melbourne. Welcome to the show.

Jackie Fairley:

Thank you.

Fintan Walton:

Starpharma Holdings is a nanotechnology company developing a range of different types of products in the healthcare field. When was the company founded? it was 10-years ago?

Jackie Fairley:

It was it's founded around 10-years ago on a particular type of technology and then in 2006 we also acquired the balance of the US business that we had an interest in.

Fintan Walton:

Right and still the basis of the business is this Dendritic technology?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jackie Fairley

Chief Executive Officer

Dr JJackie Fairley, CEO of Starpharma, has over 18 years' experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Mayne Pharma). Before joining Starpharma as COO in 2005, she was CEO of Cerylid Biosciences Limited. During her time as CEO of Cerylid, the company generated revenues of over $20 million, raised more than $10 million private equity funding and completed the acquisition and integration of a private kinase company. Prior to joining the biotechnology sector, Dr Jackie Fairleyspent 5 years as a Vice President for Faulding's injectable division where she was responsible for the group's global business development activities and injectable development program supporting product sales of more than $200 million into 70 countries. Dr. Jackie Fairley has served on several government committees including the Federal Government's Pharmaceutical Industry Working Group, Biotechnology Advisory Council and the Victorian Innovation Economy Advisory Board.

Starpharma

Starpharma Holdings Limited is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications. Starpharma's lead product is VivaGel, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes. VivaGel is at the expanded safety/Phase IIa stage of clinical development and has been granted Fast Track status by the FDA, which will accelerate the clinical and regulatory process. In addition, VivaGel has been awarded US$20.3 million by the NIH to progress the development for HIV. The NIH has provided additional funding to develop VivaGel against genital herpes. Starpharma has a 100% owned US-based subsidiary Dendritic Nanotechnologies Inc expanding the company's potential products to include drug delivery and industrial specialty chemical applications, many of which have near-term cash-flow opportunities.